Home | About IJMPO | Editorial board | Search | Ahead of print | Current Issue | Archives | Instructions | Subscribe | Advertise | Contact us |  Login 
Indian Journal of Medical and Paediatric Oncology
Search Article 
  
Advanced search 
 
COURTING CONTROVERSY
Year : 2020  |  Volume : 41  |  Issue : 6  |  Page : 901-905

Combining immunotherapy with multikinase inhibitors: A cautious new promise


Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India

Correspondence Address:
Dr. Raja Pramanik
Department of Medical Oncology, Dr. B. R.A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi - 110 029
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ijmpo.ijmpo_326_20

Rights and Permissions

Immune check point inhibitors have made a sea change in oncology practice in current times. These drugs have crossed the conventional boundaries of histology and organ of origin. Tumor agnostic approvals for mismatch repair deficient, microsatellite-instability (MSI)-H and recently tumor mutational burden-high solid tumors have been a giant leap. The Oncology community seems poised to embrace the concept of “immunotherapy for all.” Recent studies have evaluated the manipulation of tumor-associated macrophages using multi-kinase inhibitors, to make even MSI low tumor responsive to checkpoint inhibitors. With accelerated food and drug administration approvals, the promise of this combo is palpable but definitely merits caution.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed103    
    Printed3    
    Emailed0    
    PDF Downloaded25    
    Comments [Add]    

Recommend this journal